ClinicalTrials.Veeva

Menu

Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer (DIP-CAOS)

C

Caen University Hospital

Status

Not yet enrolling

Conditions

Addiction Nicotine
Psychoactive Substance Use
Anxiety Disorder/Anxiety State
Symptoms and Signs
Neuropathic Pain
Pain, Chronic
Sleep
Alcohol Use Disorder

Treatments

Other: Questionnaire

Study type

Interventional

Funder types

Other

Identifiers

NCT05505188
2020-A01894-35

Details and patient eligibility

About

Head and neck cancers are a source of complications and after-effects related to the disease and treatment. These cancers and their treatment alter the quality of life of patients and generate pain with physical and psychological components. Chronic pain affects 36% of patients at 6 months and 30% after this period. These pains are responsible for the consumption of level II and III analgesics in 53% of these patients. At the same time, after the end of treatment, nearly a quarter of patients continued to smoke and half still consumed alcohol at least twice a week.

The hypothesis of this research is to investigate the correlation between pain and the continuation of addictions, the occurrence of depressive states, asthenia and the alteration of the patients' global quality of life.

The investigators propose a two-center prospective cohort study to evaluate this hypothesis at 6 months after radiotherapy treatment.

This study is planned to include 120 patients with a first head and neck cancer whit radiotherapy as part of their treatment sequence. The expected duration of inclusion is 18 months.

The identification of factors affecting survival, quality of life and patient compliance is essential to determine appropriate management, particularly by creating appropriate therapeutic education programs.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a first Head and neck cancer whose therapeutic sequence involves radiotherapy
  • Patient over 18 years of age
  • Having given written consent
  • patient not previously treated with radiotherapy
  • Life expectancy > 3 months
  • World Health Organization (WHO) score < 3
  • Histologically proven Head and Neck cancer
  • Stable patient, with no signs of recurrence or other progressive neoplasia at the time of the examination
  • Patient treated with radiotherapy
  • Patient fluent in French

Exclusion criteria

  • Non-consenting patient
  • History of malignancy, other than treated and cured basal cell or cervical cancer
  • Patient who has had a salvage surgery other than lymph node removal
  • Patient with evidence of recurrence or other progressive neoplasia at the time of examination
  • Patient who has had previous mutilating surgery (causing sequelae of swallowing and eating)
  • Uncontrolled infectious pathology
  • Patient under 18 years of age
  • Patient who is not fluent in French
  • Patient with a psychiatric pathology that could disrupt the study or prevent the interpretation of the results.

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

120 participants in 1 patient group

Population
Other group
Description:
no arm, single cohort follow-up
Treatment:
Other: Questionnaire

Trial contacts and locations

0

Loading...

Central trial contact

Emmanuel Babin, PHD; Maxime Humbert, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems